Central oxytocin receptor stimulation attenuates the orexigenic effects of butorphanol tartrate.

Citation data:

Neuroreport, ISSN: 1473-558X, Vol: 27, Issue: 14, Page: 1012-7

Publication Year:
2016
Usage 12
Abstract Views 12
Captures 1
Exports-Saves 1
Citations 3
Citation Indexes 3
PMID:
27471903
DOI:
10.1097/wnr.0000000000000647
Author(s):
Olszewski, Pawel K, Klockars, Oscar A, Klockars, Anica, Levine, Allen S
Publisher(s):
Ovid Technologies (Wolters Kluwer Health)
Tags:
Neuroscience
article description
Butorphanol tartrate (BT), a mixed µ/κ/δ opioid receptor agonist, is one of the most potent orexigens known to date. The central mechanisms through which BT causes hyperphagia are largely unknown. Interestingly, BT suppresses meal-end activation of neurons synthesizing anorexigenic neuropeptide, oxytocin (OT), which suggests that BT promotes hyperphagia by silencing OT-derived satiety signaling. As OT terminates consumption by acting by distinct hindbrain and forebrain circuits, we investigated whether stimulation of the OT receptor in the forebrain or the hindbrain [through lateral ventricular (LV) and fourth ventricular (4V) OT injections] leads to termination of food intake induced by BT. We established effective doses of BT on chow intake in ad-libitum-fed and overnight-deprived rats as well as effective doses of LV and 4V OT in deprived animals. Then, we determined doses of LV and 4V OT that reduce hyperphagia produced by BT in sated and deprived rats. Finally, we assessed whether OT's effects on BT-induced feeding can be suppressed by an OT receptor antagonist. 4 mg/kg BT increased intake in ad-libitum-fed and overnight-deprived rats, whereas LV and 4V OT at 1 μg caused a decrease in deprived rats. BT-induced chow intake in hungry and sated animals was suppressed by a very low, 0.1 μg dose of 4V OT, whereas 1 μg OT was effective LV. The effect of OT was attenuated by OT receptor antagonist, L-368 899. Reduced activity of the OT circuit, especially its hindbrain component, is a critical factor in shaping the magnitude of consumption in response to BT treatment.

This article has 0 Wikipedia mention.